Mofezolac Property

Melting point:

147.5℃

Boiling point:

527.2±50.0 °C(Predicted)

Density 

1.250±0.06 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

DMSO: soluble

form 

A solid

pka

pKa ~3.3(at 25℃)

Safety

Toxicity

LD50 in male, female mice, male, female rats (mg/kg): 1528, 1740, 920, 887 orally; 275, 321, 378, 342 i.p.; 612, 545, 572, 510 s.c. (Satoh)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H317May cause an allergic skin reaction

H319Causes serious eye irritation

Precautionary statements

P280Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Mofezolac Chemical Properties,Usage,Production

Description

Mofezolac is a new non-steroidal analgesic antiinflammatory agent introduced in Japan for the treatment of post-operative and post-traumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. In in vfim studies, mofezolac inhibits prostaglandin biosynthesis and platelet aggregation, reportedly through the inhibition of cyclooxygenase. In animal studies, mofezolac showed more potent suppression in various writhing models than agents such as ibuprofen, mefenamic acid and aspirin. Mofezolac also has a potent inhibitory activity on the algesic responses induced by the mechanical stimulus of the inflamed tissue. The ulcerogenic effect of mofezolac on the gastric mucosa is far weaker than that of indomethacin and other agents.

Originator

Pasteur Merieux (France)

Definition

ChEBI: Mofezolac (TN) is a member of methoxybenzenes.

brand name

Disopain

Clinical Use

Yoshitomi (now Mitsubishi Pharma) has launched mofezolac, a COX-1 inhibitor with preferential COX-1 inhibition for the treatment of arthritis-related pain in Japan. The compound is used in oral doses of 75mg for the treatment of periarthritis, lumbago, neckshoulder- arm syndrome and pain after surgery, trauma, or dental extraction.

Synthesis

The reaction of deoxyanisoin with hydroxylamine in methanol gives the corresponding 1,2-bis(4-methoxyphenyl)ethanone oxime, which is cyclized with ethyl acetate by means of n-butyllithium in tetrahydrofuran yielding 3,4-di(4-methoxyphenyl)-5-methylisoxazole. Finally, this compound is condensed with CO2 with n-butyllithium as catalyst in tetrahydrofuran to yield mofezolac . The synthesis with ClCO2C2H5 instead of CO2 is described in .